INOTIV INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inotiv, Inc. (NasdaqCM: NOTV). On November 5, 2021, the Company completed its purchase of Envigo RMS, LLC (“Envigo”) after several months of discussion and due diligence reviews. However, from July 2021 onward, Envigo's Cumberland Facility had been charged with numerous serious violati.
- 05/03/2024
|
Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024
- WEST LAFAYETTE, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, on Friday, May 10, 2024, before the opening of the stock market. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results.
- 04/29/2024
|
INOTIV INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV
- NEW ORLEANS, La. , April 19, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
- 04/19/2024
|
INOTIV INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inotiv, Inc. (NasdaqCM: NOTV). On November 5, 2021, the Company completed its purchase of Envigo RMS, LLC (“Envigo”) after several months of discussion and due diligence reviews. However, from July 2021 onward, Envigo's Cumberland Facility had been charged with numerous serious violati.
- 04/05/2024
|
Inotiv (NOTV) Is a Great Choice for 'Trend' Investors, Here's Why
- If you are looking for stocks that are well positioned to maintain their recent uptrend, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 04/03/2024
|
Why Fast-paced Mover Inotiv (NOTV) Is a Great Choice for Value Investors
- If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- 04/02/2024
|
Is Inotiv (NOTV) a Great Value Stock Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 03/25/2024
|
Here's Why Momentum in Inotiv, Inc. (NOTV) Should Keep going
- Inotiv, Inc. (NOTV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
- 03/18/2024
|
Rocket Stocks: 3 Picks That Could Skyrocket Your Portfolio by 2025
- In the stock market, identifying the next big opportunity is like observing a celestial phenomenon. Today, through the cosmos of investment, three shining stars are identified for their potential for astronomical valuation possibilities.
- 03/12/2024
|
3 Stocks That Could Fast-Track Your Millionaire Status
- While making investments, efforts for wealth often resemble strategic gaming; here, picking the right stocks can significantly influence one's financial reach. Amidst the vast options, three stocks are the catalysts for transforming fortunes.
- 03/07/2024
|
Inotiv, Inc. (NOTV) is a Great Momentum Stock: Should You Buy?
- Does Inotiv, Inc. (NOTV) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 03/07/2024
|
Despite Fast-paced Momentum, Inotiv, Inc. (NOTV) Is Still a Bargain Stock
- Inotiv, Inc. (NOTV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- 03/07/2024
|
Should Value Investors Buy Inotiv (NOTV) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 03/01/2024
|
3 Overlooked Stocks with Potential for 500% Growth by 2025
- In between the noise, fear of missing out and hype in stock markets, specific opportunities usually slip under the radar. These overlooked stocks move within the depths of lesser-known layers of the market.
- 02/27/2024
|
Millionaire-Makers: 3 Game-Changing Stocks Ready for Historic Gains
- In the vast opportunities, certain stocks emerge as hidden gems, promising solid returns and the potential to redefine and deliver historic gains. The article lists three game-changing stocks and the companies at the edge of their industry progress.
- 02/20/2024
|
Inotiv, Inc. (NOTV) Is Attractively Priced Despite Fast-paced Momentum
- Inotiv, Inc. (NOTV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- 02/19/2024
|
Are Investors Undervaluing Inotiv (NOTV) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 02/14/2024
|
Inotiv, Inc. (NOTV) Reports Q1 Loss, Lags Revenue Estimates
- Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of $0.07. This compares to loss of $1.28 per share a year ago.
- 02/07/2024
|
Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024
- WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, on Wednesday, February 7, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
- 01/29/2024
|
Inotiv: The Business Is Recovering, The Stock Will Follow
- NOTV stock has significantly dropped due to a supply chain shock, but the current price remains far below its estimated fair value. The company's fundamental recovery is in place, with strong financial performance and positive guidance for 2024. The stock price is lagging behind the company's performance, creating an opportunity for investors to potentially make 3-5x returns.
- 12/24/2023
|
Inotiv, Inc. (NOTV) Shows Fast-paced Momentum But Is Still a Bargain Stock
- Inotiv, Inc. (NOTV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- 12/15/2023
|
Inotiv, Inc. (NOTV) Q4 2023 Earnings Call Transcript
- Inotiv, Inc. (NASDAQ:NOTV ) Q4 2023 Earnings Conference Call December 11, 2023 4:30 PM ET Company Participants Bob Yedid - LifeSci Advisors, Investor Relations Bob Leasure - Chief Executive Officer, President, and Director Beth Taylor - Senior Vice President of Finance and Chief Financial Officer Conference Call Participants Tim Daley - Wells Fargo Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Dave Windley - Jefferies Operator Greetings, and welcome to the Inotiv's Fourth Quarter and Full Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.
- 12/11/2023
|
Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023
- WEST LAFAYETTE, Ind., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 fourth quarter and full year ended September 30, 2023, on Monday, December 11, 2023, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
- 11/27/2023
|
Inotiv Provides Business Updates and Upcoming Investor Conferences Update
- WEST LAFAYETTE, Ind., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provides business updates related to Inotiv's operations and an update regarding its participation in upcoming investor conferences.
- 11/13/2023
|
Inotiv, Inc. to Participate in Upcoming Investor Conferences
- WEST LAFAYETTE, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in multiple upcoming investor conferences throughout November 2023.
- 11/01/2023
|
Inotiv, Inc. to Participate in Upcoming September 2023 Investor Conferences
- WEST LAFAYETTE, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in multiple upcoming investor conferences throughout September 2023.
- 08/24/2023
|
Inotiv, Inc. (NOTV) Q3 2023 Earnings Call Transcript
- Inotiv, Inc. (NASDAQ:NOTV ) Q3 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Bob Yedid - LifeSci Advisors, Investor Relations Bob Leasure - Chief Executive Officer, President, and Director Beth Taylor - Senior Vice President of Finance and Chief Financial Officer Conference Call Participants Tim Daley - Wells Fargo Matt Hewitt - Craig-Hallum Dave Windley - Jefferies Frank Takkinen - Lake Street Capital Markets Yuan Zhi - B. Riley Operator Good afternoon, ladies and gentlemen.
- 08/10/2023
|
Inotiv, Inc. (NOTV) Q3 Earnings Miss Estimates
- Inotiv, Inc. (NOTV) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.26 per share. This compares to loss of $0.15 per share a year ago.
- 08/10/2023
|
Inotiv, Inc. to Report Fiscal 2023 Third Quarter Financial Results and Host Conference Call on Thursday, August 10, 2023
- WEST LAFAYETTE, Ind., July 24, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
- 07/24/2023
|
Strength Seen in Inotiv, Inc. (NOTV): Can Its 34.5% Jump Turn into More Strength?
- Inotiv, Inc. (NOTV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 07/21/2023
|
Does Inotiv, Inc. (NOTV) Have the Potential to Rally 185.14% as Wall Street Analysts Expect?
- The consensus price target hints at an 185.1% upside potential for Inotiv, Inc. (NOTV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 06/05/2023
|
5 High Earnings Yield Gems for Successful Value Investing
- In the realm of value investing, the earnings yield metric serves as a powerful tool for identifying undervalued stocks with solid long-term growth potential. CCU, WNC, LOMA, JKS and NOTV are worth buying.
- 05/31/2023
|
Here Is Why Bargain Hunters Would Love Fast-paced Mover Inotiv, Inc. (NOTV)
- Inotiv, Inc. (NOTV) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
- 05/30/2023
|
Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference
- WEST LAFAYETTE, Ind., May 25, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will present at the Jefferies Healthcare Conference, being held in New York, NY, from June 7-9, 2023. Management will also be available for one-on-one meetings.
- 05/25/2023
|
Inotiv, Inc. to Participate in May Investor Conferences
- WEST LAFAYETTE, Ind., May 19, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today its participation in the following investor conferences:
- 05/19/2023
|
Wall Street Analysts Predict a 168.98% Upside in Inotiv, Inc. (NOTV): Here's What You Should Know
- The average of price targets set by Wall Street analysts indicates a potential upside of 169% in Inotiv, Inc. (NOTV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 05/18/2023
|
Inotiv, Inc. (NOTV) Q2 2023 Earnings Call Transcript
- Inotiv, Inc. (NASDAQ:NOTV ) Q2 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Devin Sullivan – Investor Relations-The Equity Group Bob Leasure – President and Chief Executive Officer Beth Taylor – Chief Financial Officer Conference Call Participants Matt Hewitt – Craig-Hallum Dave Windley – Jefferies Frank Takkinen – Lake Street Capital Markets Operator Good afternoon, and welcome to Inotiv's Second Quarter Fiscal 2023 Financial Results Conference Call. At this time all participants are in listen-only mode.
- 05/11/2023
|
Inotiv, Inc. to Report Fiscal 2023 Second Quarter Financial Results and Host Conference Call on Thursday, May 11, 2023
- WEST LAFAYETTE, Ind., April 26, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, on Thursday, May 11, 2023, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
- 04/26/2023
|
Inotiv, Inc. (NOTV) Q1 2023 Earnings Call Transcript
- Inotiv, Inc. (NASDAQ:NOTV ) Q1 2023 Earnings Conference Call February 13, 2023 4:30 PM ET Company Participants Devin Sullivan - The Equity Group Inc. Bob Leasure - President and Chief Executive Officer Beth Taylor - Senior Vice President and Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Frank Takkinen - Lake Street Capital Markets David Windley - Jefferies Tim Daley - Wells Fargo Operator Hello, and welcome to Inotiv Inc.'s First Quarter Fiscal 2023 Financial Results Conference Call and Webcast. A question-and-answer session will follow the formal presentation.
- 02/13/2023
|
Inotiv, Inc. to Report Fiscal 2023 First Quarter Financial Results and Host Conference Call on Monday, February 13, 2023
- WEST LAFAYETTE, Ind., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022 on Monday, February 13, 2023 after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
- 02/06/2023
|
Inotiv: Turning Focus To Organic Growth
- The stock may have found its bottom in December 2022. Revenue jumped 400 percent in the fourth fiscal quarter, but earnings plummeted.
- 01/17/2023
|
Inotiv: High Expenses Likely To Impair Long-Term Profitability
- Inotiv's recently acquired companies cause its revenue to spike tremendously. However, the company's expenses are just as great, and not all of the largest cost items are one-time costs, meaning the company could remain unprofitable for a long time.
- 01/16/2023
|
Inotiv, Inc. (NOTV) Q4 2022 Results - Earnings Call Transcript
- Inotiv, Inc. (NASDAQ:NOTV ) Q4 2022 Earnings Conference Call January 10, 2023 5:00 PM ET Company Participants Devin Sullivan - Investor Relations, The Equity Group Inc. Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Dave Windley - Jefferies Operator Greetings, and welcome to the Inotiv, Inc.'s Fourth Quarter and Full Year Fiscal 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
- 01/10/2023
|
Inotiv, Inc. to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results and Host Conference Call on Tuesday, January 10, 2023
- WEST LAFAYETTE, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 fourth quarter and full year ended September 30, 2022 on Tuesday, January 10, 2023 after the close of the stock market. The Company will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.
- 01/04/2023
|
Inotiv, Inc. to Report Fourth Quarter Fiscal 2022 Financial Results and Host Conference Call on Monday, December 12, 2022
- WEST LAFAYETTE, Ind., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 fourth quarter ended September 30, 2022, on Monday, December 12, 2022, after the close of the stock market. The Company will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.
- 11/28/2022
|
Inotiv, Inc. to Participate in November Investor Conferences
- WEST LAFAYETTE, Ind., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences during the month of November:
- 11/01/2022
|
Inotiv, Inc. to Participate in September Investor Conferences
- WEST LAFAYETTE, Ind., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences during the month of September:
- 08/31/2022
|
Inotiv, Inc. (NOTV) CEO Bob Leasure on Q3 2022 Results - Earnings Call Transcript
- Inotiv, Inc. (NASDAQ:NOTV ) Q3 2022 Earnings Conference Call August 10, 2022 5:00 PM ET Company Participants Devin Sullivan - The Equity Group Inc. Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matthew Hewitt - Craig-Hallum Capital Group David Windley - Jefferies Operator Greetings. Welcome to Inotiv, Inc.'s Third Quarter Fiscal 2022 Financial Results Conference Call.
- 08/10/2022
|
Inotiv, Inc. to Report Third Quarter Fiscal 2022 Financial Results and Host Conference Call on Wednesday, August 10, 2022
- WEST LAFAYETTE, Ind., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 third quarter ended June 30, 2022, on Wednesday, August 10, 2022, after the close of the stock market. The Company will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.
- 08/01/2022
|
Inotiv, Inc. to Participate in Upcoming Investor Conferences
- WEST LAFAYETTE, Ind., May 16, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences:
- 05/16/2022
|
Inotiv, Inc. (NOTV) CEO Bob Leasure on Q2 2022 Results - Earnings Call Transcript
- Inotiv, Inc. (NASDAQ:NOTV ) Q2 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Kalle Ahl - The Equity Group Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Capital Group Operator Greetings. Welcome to Inotiv, Incorporated's Second Quarter Fiscal 2022 Financial Results conference call.
- 05/12/2022
|
Inotiv, Inc. to Report Second Quarter Fiscal 2022 Financial Results and Host Conference Call on Thursday, May 12, 2022
- WEST LAFAYETTE, Ind., April 26, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 second quarter ended March 31, 2022, on Thursday, May 12, 2022, after the close of the stock market and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.
- 04/26/2022
|
5 Stocks Insiders Are Charging Up for Spring
- According to the Insider Cluster Buys Screen, a Premium feature of GuruFocus, five stocks with high insider buys over the past two months include Primis Financial Corp. ( FRST , Financial), James River Group Holdings Ltd. ( JRVR , Financial), Reservor Media Inc. ( RSVR , Financial), Utz Brands Inc. ( UTZ , Financial) and Inotiv Inc. ( NOTV , Financial).
- 03/18/2022
|
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
- Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.
- 02/25/2022
|
Inotiv, Inc. (NOTV) CEO Bob Leasure on Q1 2022 Results Earnings Call Transcript
- Inotiv, Inc. (NOTV) CEO Bob Leasure on Q1 2022 Results Earnings Call Transcript
- 02/10/2022
|
Inotiv: Leading Mid-Market CRO Ups Its Game
- Inotiv is a leading mid-market CRO offering a full suite of non-clinical services. The Company has been on an acquisition spree, latest being Envigo, upping its game to full programs.
- 02/07/2022
|
Inotiv, Inc. (NOTV) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Inotiv, Inc. (NOTV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 01/25/2022
|
Inotiv, Inc. (NOTV) CEO Bob Leasure on Q4 2021 Results - Earnings Call Transcript
- Inotiv, Inc. (NOTV) CEO Bob Leasure on Q4 2021 Results - Earnings Call Transcript
- 12/17/2021
|
Inotiv: Q4 Earnings Insights
- Inotiv (NASDAQ:NOTV) reported its Q4 earnings results on Thursday, December 16, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
- 12/16/2021
|
A Preview Of Inotiv's Earnings
- Inotiv (NASDAQ:NOTV) is set to give its latest quarterly earnings report on Thursday, 2021-12-16. Here's what investors need to know before the announcement.
- 12/15/2021
|
Inotiv, Inc. Reschedules Fourth Quarter Fiscal 2021 Financial Results and Conference Call for Thursday, December 16, 2021
- WEST LAFAYETTE, Ind., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2021 fourth quarter ended September 30, 2021, on Thursday, December 16, 2021, after the close of the stock market and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.
- 12/13/2021
|
Inotiv Stock (NOTV): Why The Price Surged Today
- The stock price of Inotiv Inc (NASDAQ: NOTV) increased by over 19% during intraday trading today. This is why it happened.
- 12/08/2021
|
Bears are Losing Control Over Inotiv, Inc. (NOTV), Here's Why It's a 'Buy' Now
- Inotiv, Inc. (NOTV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 12/07/2021
|
Inotiv Earnings Preview
- Inotiv (NASDAQ:NOTV) is set to give its latest quarterly earnings report on Tuesday, 2021-12-07. Here's what investors need to know before the announcement.
- 12/06/2021
|
Inotiv, Inc. to Report Fourth Quarter Fiscal 2021 Financial Results and Host Conference Call on Tuesday, December 7, 2021
- WEST LAFAYETTE, Ind., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2021 fourth quarter ended September 30, 2021, on Tuesday, December 7, 2021, after the close of the stock market and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.
- 11/29/2021
|
Inotiv, Inc. to Participate in Upcoming Investor Conferences
- WEST LAFAYETTE, Ind., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences:
- 11/02/2021
|
NOTV Stock: Why It Increased This Week
- The stock price of Inotiv Inc (NASDAQ: NOTV) increased by over 7% this week. This is why it happened.
- 10/06/2021
|
Inotiv, Inc. Announces Expansion of In Vivo Pharmacology Offering with Acquisition of Plato BioPharma, Inc.
- WEST LAFAYETTE, Ind., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the acquisition of Plato BioPharma, Inc. (“PBI”), a Colorado-based, in vivo pharmacology research and drug discovery company specializing in cardiovascular, renal, pulmonary and hepatic therapeutic areas. Transaction consideration totaled $15.0 million, consisting of: $10.0 million in cash; 57,587 Inotiv common shares having a value of $2.0 million based on the weighted average closing price of Company shares as reported by NASDAQ for the twenty trading-day period ending on September 29, 2021; and $3.0 million in unsecured promissory notes.
- 10/04/2021
|
Inotiv, Inc. Announces Closing of $125 Million Convertible Senior Notes Offering and Full Exercise of Option to Purchase Additional $15 Million of Notes
- WEST LAFAYETTE, Ind., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the closing of its offering of $140,000,000 aggregate principal amount of 3.25% convertible senior notes due 2027 (the “notes”), including $15,000,000 of additional notes, in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company's obligations under the notes are guaranteed by BAS Evansville, Inc., a wholly owned subsidiary of the Company.
- 09/27/2021
|
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Inotiv, Inc. - NOTV
- NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Inotiv, Inc. ("NOTV" or the "Company") (NOTV )relating to its proposed merger with Envigo RMS Holding Corp. Under the terms of the agreement, NOTV shareholders are expected to own 64% of the combined company.
- 09/27/2021
|
Inotiv Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Inotiv, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NOTV
- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Inotiv, Inc. (NASDAQ: NOTV) and Envigo RMS Holding Corp. is fair to Inotiv shareholders. Upon closing of the transaction, Inotiv shareholders are expected to own approximately 64% of the combined company on a fully diluted basis. Halper Sadeh encourages Inotiv shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper
- 09/23/2021
|
Inotiv, Inc. Prices Upsized $125 Million Convertible Senior Notes Offering
- WEST LAFAYETTE, Ind., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the pricing of its offering of $125,000,000 aggregate principal amount of 3.25% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $110,000,000 aggregate principal amount of notes. The notes will be fully and unconditionally guaranteed, on a senior, unsecured basis, by BAS Evansville, Inc., a wholly owned subsidiary of Inotiv (the “guarantor”). The issuance and sale of the notes are scheduled to settle on September 27, 2021, subject to customary closing conditions. Inotiv also granted the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $15,000,000 principal amount of notes.
- 09/22/2021
|
Inotiv, Inc. Announces Proposed Convertible Senior Notes Offering
- WEST LAFAYETTE, Ind., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced its intention to offer, subject to market and other conditions, $110,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The notes will be fully and unconditionally guaranteed, on a senior, unsecured basis, by BAS Evansville, Inc., a wholly owned subsidiary of Inotiv (the “guarantor”). Inotiv also expects to grant the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $16,500,000 principal amount of notes.
- 09/21/2021
|
Inotiv Scoops Up Envigo For $200M To Enhance Research, Drug Discovery Solutions
- Inotiv Inc (NASDAQ:NOTV), a contract research organization, has agreed to acquire Envigo RMS Holding Corp in a cash and stock transaction. Envigo is a provider of research models and services.
- 09/21/2021
|
NOTV Stock: Why It Significantly Increased Today
- The stock price of Inotiv Inc (NASDAQ: NOTV) significantly increased today. This is why it happened.
- 09/21/2021
|
Inotiv, Inc. and Envigo Propose to Join Forces to Enhance Research and Drug Discovery Solutions
- -- Expected to establish a leading global provider of a full spectrum of pre-clinical solutions -- -- Expected to be immediately accretive to Inotiv earnings and margins before synergies --
- 09/21/2021
|
Inotiv, Inc. to Participate in the 2021 Colliers Institutional Investor Conference
- WEST LAFAYETTE, Ind., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the 2021 Colliers Institutional Investor Conference, which will be held virtually, on Thursday, September 9, 2021.
- 08/31/2021
|
Inotiv: Q3 Earnings Insights
- Shares of Inotiv (NASDAQ:NOTV) fell 1.0% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 87.50% year over year to ($0.15), which missed the estimate of ($0.08).
- 08/11/2021
|
Inotiv, Inc.'s (NOTV) CEO Robert Leasure on Q3 2021 Results - Earnings Call Transcript
- Inotiv, Inc.'s (NOTV) CEO Robert Leasure on Q3 2021 Results - Earnings Call Transcript
- 08/11/2021
|
Inotiv, Inc. Announces Acquisition of Gateway Pharmacology Laboratories
- WEST LAFAYETTE, Ind., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the acquisition of Gateway Pharmacology Laboratories LLC (“Gateway Pharmacology”), effective August 2, 2021. The acquisition is a strategic element of the Company's previously announced St. Louis operations expansion, designed to include laboratories for increased drug metabolism & pharmacokinetics (DMPK) technology and capability, as well as a new cell and molecular biology suite capable of delivering in vitro solutions in pharmacology and toxicology early in drug discovery.
- 08/02/2021
|
Inotiv Acquires Laboratory Instrumentation for Discovery and Development of Novel Therapies
- WEST LAFAYETTE, Ind., July 15, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV ) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and bioanalytical drug discovery and development services, today announced that the Company has purchased the physical assets of a Tennessee-based laboratory services provider that ceased operations. The assets, which include lab instrumentation, stock consumables and chemicals, lab benchwork, and office furniture, were acquired for approximately $1.3 million, a substantial discount to the Company's estimate of fair market value.
- 07/15/2021
|
Inotiv Acquires Genetic Toxicology Assets from MilliporeSigma's BioReliance® portfolio
- WEST LAFAYETTE, Ind., July 12, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that the Company has acquired key genetic toxicology assets from MilliporeSigma's BioReliance® portfolio, including standard operating procedures, stock cultures, historic control data and client list. While Inotiv did not disclose the specific financial terms, the transaction consists of a sales-based royalty agreement and does not require upfront funding from the Company.
- 07/12/2021
|
Inotiv, Inc. Broadens Pathology Services to Include Medical Device Pathology and Hires Nicolette Jackson to Lead Effort
- WEST LAFAYETTE, Ind., June 28, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the expansion of the Company's pathology services to include medical device pathology. Nicolette Jackson, DVM, MS, DACVP, has joined the Company as Director, Medical Device Pathology, to lead this effort.
- 06/28/2021
|
Inotiv Set to Join Russell 3000® Index and Russell 2000® Index
- WEST LAFAYETTE, Ind., June 07, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that the Company is set to join the broad-market Russell 3000® Index and Russell 2000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. markets open on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.
- 06/07/2021
|
Inotiv Announces Purchase of St. Louis Facility and Plans to Expand Capacity
- WEST LAFAYETTE, Ind., May 27, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that the Company has completed the purchase of its previously leased St. Louis facility for approximately $4.7 million.
- 05/27/2021
|
Inotiv, Inc. (NOTV) CEO Robert Leasure on Q2 2021 Results - Earnings Call Transcript
- Inotiv, Inc. (NOTV) CEO Robert Leasure on Q2 2021 Results - Earnings Call Transcript
- 05/08/2021
|
Inotiv, Inc. Announces Second Quarter Fiscal 2021 Financial Results
- WEST LAFAYETTE, Ind., May 05, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced financial results for the three months (“Q2 FY 2021”) and six months (“H1 FY 2021”) ended March 31, 2021.
- 05/05/2021
|
Inotiv, Inc. Announces Debt Financing and Completion of Acquisitions of HistoTox Labs, Inc. and Bolder BioPATH, Inc.
- WEST LAFAYETTE, Ind., April 30, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that the Company has secured $28.0 million in debt financing from First Internet Bank of Indiana and completed the previously-announced acquisition of substantially all of the assets of HistoTox Labs, Inc. (“HistoTox Labs”) and the acquisition by merger of Bolder BioPATH, Inc. (“Bolder BioPATH”), effective April 30, 2021.
- 04/30/2021
|
Inotiv, Inc. to Report Second Quarter Fiscal 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
- WEST LAFAYETTE, Ind., April 26, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that the Company will issue its financial results press release for the fiscal 2021 second quarter ended March 31, 2021, on Wednesday, May 5, 2021, after the close of the stock market and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.
- 04/26/2021
|
Inotiv, Inc. Announces Closing of Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
- WEST LAFAYETTE, Ind., April 23, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the closing of an underwritten public offering of 3,044,117 of its common shares, including 397,058 common shares sold pursuant to the full exercise by the underwriter of its option to purchase additional shares to cover over-allotments. All of the shares were sold at a price to the public of $17.00 per share. The gross proceeds to the Company from this offering, before deducting the underwriting discount and offering expenses payable by the Company, were approximately $51.7 million.
- 04/23/2021
|
NOTV Stock: Over 15% Decrease Pre-Market Explanation
- The stock price of Inotiv, Inc. (NASDAQ: NOTV) fell by over 15% pre-market. This is why it happened.
- 04/21/2021
|
Inotiv, Inc. Announces Pricing of Public Offering of 2,647,059 Common Shares
- WEST LAFAYETTE, Ind., April 21, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the pricing of an underwritten public offering of 2,647,059 of its common shares at a price to the public of $17.00 per share. The gross proceeds to the Company from this offering, before deducting the underwriting discount and offering expenses payable by the Company, are expected to be approximately $45.0 million. All of the shares are being offered by the Company. The offering is expected to close on or about April 23, 2021. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 397,058 of its common shares at the public offering price, less the underwriting discount.
- 04/21/2021
|
Inotiv, Inc. Announces Proposed Public Offering of Common Shares
- WEST LAFAYETTE, Ind., April 20, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that it intends to offer and sell its common shares in an underwritten public offering. In connection with this proposed offering, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the common shares to be sold in the proposed offering at the public offering price, less the underwriting discount. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. All of the shares are being offered by the Company.
- 04/20/2021
|
Inotiv, Inc. Announces Select Preliminary Unaudited Financial Results for Second Quarter and Year to Date Fiscal 2021
- WEST LAFAYETTE, Ind., April 20, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced select preliminary unaudited financial results for the second quarter and six months ended March 31, 2021.
- 04/20/2021
|
Inotiv, Inc. Announces Expansion of Pharmacology and Pathology Offerings with Agreement to Purchase Bolder BioPATH, Inc.
- WEST LAFAYETTE, Ind., April 16, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of non-clinical and analytical contract research services, today announced that the Company has entered into an agreement and plan of merger with Bolder BioPATH, Inc. (“Bolder BioPATH”), a contract pharmacology and pathology company specializing in in vivo models of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, diseases of the central nervous system and other autoimmune, inflammation, and pain models.
- 04/16/2021
|
Inotiv, Inc. Enhances Histopathology Offering with Announcement of Agreement to Purchase HistoTox Labs, Inc.
- WEST LAFAYETTE, Ind., April 13, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of nonclinical and analytical contract research services, today announced that the Company has entered into an agreement to purchase substantially all of the assets of HistoTox Labs, Inc. (“HistoTox Labs”), a full-service histopathology contract research organization (“CRO”) offering medically relevant non-clinical and clinical services to the pharmaceutical, biotech, and academic communities.
- 04/13/2021
|